Thomas J. Schall
2020
In 2020, Thomas J. Schall earned a total compensation of $8.4M as President and Chief Executive Officer at ChemoCentryx, a 150% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $424,200 |
---|---|
Option Awards | $2,400,162 |
Salary | $707,000 |
Stock Awards | $4,831,383 |
Other | $3,564 |
Total | $8,366,309 |
Schall received $4.8M in stock awards, accounting for 58% of the total pay in 2020.
Schall also received $424.2K in non-equity incentive plan, $2.4M in option awards, $707K in salary and $3.6K in other compensation.
Rankings
In 2020, Thomas J. Schall's compensation ranked 1,095th out of 13,090 executives tracked by ExecPay. In other words, Schall earned more than 91.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 1,095 out of 13,090 | 92nd |
Division Manufacturing | 381 out of 5,624 | 93rd |
Major group Chemicals And Allied Products | 132 out of 2,257 | 94th |
Industry group Drugs | 116 out of 1,957 | 94th |
Industry Pharmaceutical Preparations | 86 out of 1,462 | 94th |
Source: SEC filing on April 5, 2022.
Schall's colleagues
We found two more compensation records of executives who worked with Thomas J. Schall at ChemoCentryx in 2020.